Samsung Bioepis and Teva Expand SB41 and SB44 Biosimilar Partnership | Lucid Diligence Brief
This Lucid Diligence Brief explores Samsung Bioepis’ expansion of its…
QC Healthcare–Sanguina Collaboration: Can Digital Biomarkers Scale? | Lucid Diligence Brief
This Lucid Diligence Brief examines the QC Healthcare–Sanguina digital…
Evogene and ELEO Oral PCSK9 Collaboration | Lucid Diligence Brief
Evogene and ELEO Oral PCSK9 discovery collaboration launches as Merck’s…
AdaptHealth Diabetes Health Divestiture to Cardinal Health | Lucid Diligence Brief
AdaptHealth exits its Diabetes Health business in a $235 million deal as…
Servier Completes Edgewise Muscular Dystrophy Acquisition | Lucid Diligence Brief
Servier Completes the Edgewise Muscular Dystrophy Acquisition and Adds…
Warburg Pincus PANTHERx Rare Acquisition | Lucid Diligence Brief
Warburg Pincus to acquire control of PANTHERx Rare, backing expansion of the…
United Therapeutics’ Thymmune acquisition | Lucid Diligence Brief
United Therapeutics adds Thymmune’s iPSC thymic-cell platform to its…
Insilico Takeda AI Drug Discovery Deal | Lucid Diligence Brief
Insilico and Takeda test whether Pharma.AI can convert discovery speed into…
SERB–Hansa Idefirix Deal | Lucid Diligence Brief
SERB’s Idefirix rights acquisition from Hansa Biopharma sharpens its rare…
Innovent-Lilly Verzenios China Commercialization | Lucid Diligence Brief
Innovent takes mainland China commercial responsibility for Verzenios as Lilly…
Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Bionyra Pharma launched with $165M to advance TL1A, IL-23 and IL-25 biologics…
AbbVie's Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
AbbVie’s Apogee deal adds zumilokibart and asthma assets as immunology growth…